

Special Article

Management of Chronic Idiopathic Urticaria

Balachandran J

Associate Professor
Department of Pulmonary Medicine
Travancore Medical College, Kollam

Key words: Urticaria, Chronic urticaria, Idiopathic urticaria, Antihistamines

Urticaria is characterized by wheals, which are superficial itchy swelling of the skin due to transient plasma leakage from small blood vessels. Angio-oedema occurs when the deeper dermis is affected. Urticaria and Angio-oedema can occur alone or in combination.

Appearance of wheals on a recurrent basis more than twice a week and lasting over 6 weeks is Chronic Urticaria. Wheals lasting less than 6 weeks is Acute Urticaria. Urticaria can also be episodic¹. Chronic Urticaria can last from a few months to several years.

Acute Urticaria: Usually no tests are required for its evaluation. The treatment consists of H1 Anti histamine (oral/parenteral), steroids (oral/parenteral) and Adrenaline.

Episodic or Intermittent Urticaria: Here investigations for Type 1 Allergy (especially food allergens) may be useful. Skin prick test or RAST is done for the detection of allergens. Treatment is the same as in Acute Urticaria. Use of medication is as required.

Classification of Chronic Urticaria

1. Idiopathic - the great majority of CU is idiopathic. The probable aetiological agents may be Immune or Non-Immune². The causative agent cannot be identified in most cases.

2. Physical - eg: Delayed pressure urticaria

3. Special types eg: Cholinergic urticaria

4. Diseases related to urticaria eg: Vasculitis

Probable causative agents in chronic Idiopathic urticaria³ are-

1) Immune

- (a) IgE dependent - This is seen rarely in Chronic Urticaria (though common in Acute and Episodic urticaria)
- (b) Auto Immune - Constitutes one third of Idiopathic urticaria. Association with Hashimoto's thyroiditis is well documented.

2) Non-Immune

- (a) Food pseudo allergens - Non IgE mediated hypersensitivity to food additives and some natural substances found in fruits, vegetables and spices.
- (b) NSAIDs
- (c) ACE Inhibitors
- (d) Opioids

Role of Infections: Role of Helicobacter pylori and parasitic diseases has been proposed, but not proven^{5,6}.

Psychological stress has also been postulated^{3,7}.

Investigations

A detailed clinical evaluation is found to be more useful than laboratory tests in the evaluation of chronic urticaria. In general laboratory tests are not useful⁸. However in some cases it may be possible to identify the aetiology as in Urticarial vasculitis. It may also help to identify any associated auto immune disorder. The tests indicated are:

1. Blood counts
2. ESR
3. Thyroid function tests
4. Serological tests
5. Skin biopsy

6. ASST (Autologous serum skin test)

7. Allergy tests

Estimation of C1 esterase inhibitor is useful only in angioedema without wheals.

Treatment

The ideal management of Chronic Urticaria would be identifying and eliminating the underlying causes and/or eliciting triggers. However this is not possible in the great majority of cases.

Role of Dietary management in Idiopathic urticaria⁴: In the case of Type 1 hypersensitivity, avoidance of triggering agent benefits within 48 hours. But this type is rare in Chronic Urticaria. In pseudo allergy, benefit will appear usually after 3 weeks of stopping the food. Diet with low pseudo allergens is advised in Chronic Urticaria.

The drugs used in the treatment of Chronic Urticaria are Antihistamines, Anti leukotrienes, Immuno suppressants and Omalizumab. Plasmapheresis is useful in Auto immune urticaria.

Antihistamines - The most effective treatment is symptom relief and antihistamines are the most important drugs in Chronic Urticaria.

Histamine is one of the key mediators released from mast cells and basophils⁹. It has an important role in allergic diseases including urticaria. Histamine1 (H1) receptor stimulation is responsible for most of the manifestations of urticaria namely, pruritus, vasodilation, vascular permeability, hypotension and flushing. Histamine2 (H2)receptor stimulation is involved in the manifestation of pruritus and flushing¹⁰.

Antihistamines alleviate itching and reduce the number, size and duration of urticarial lesions. H1 activity in the afferent C nerve fibres cause itching which is mostly relieved by all antihistamines. Axonic reflexes of skin cause erythema. Receptors in the endothelium of post capillary venules cause extravasation (and wheal) formation. Anti inflammatory actions of Antihistamines are by two mechanisms:-1) Stabilization of mast cell and basophil cell membranes^{11,12} and 2) Inhibition of cytoplasmic transcription factors¹³.

Which Antihistamine to choose?

There are two groups of Antihistamines - the older sedating 1st generation antihistamines and the newer less (non) sedating 2nd generation antihistamines

1st generation antihistamines¹⁴: All drugs of this group are sedating. They are generally regarded safe by health care professionals because of their long standing use. But they decrease REM sleep, impair learning and work efficiency. They have been implicated in accidents (motor, aviation, boating). Deaths have been reported due to accidental overdosing in infants and adults. Intentional overdosing has also been reported in adult deaths. Some exhibit cardio toxicity in over dosage. Their duration of action is short. They have anti cholinergic side effects too.

The advantage of 1st generation antihistamines is that parenteral preparation is available which is useful in some cases of Acute Urticaria. If sedation is needed for insomnia in a patient with Chronic Urticaria, 1st generation antihistamines may be administered at bed time either alone or if necessary, along with a morning dose of 2nd generation antihistamines.

Hydroxyzine, Diphenhydramine, Chlorpheniramine and Promethazine are the drugs belonging to 1st generation antihistamines.

2nd generation antihistamines^{15,16}: They are a heterogenous group of compounds. In contrast to the highly lipophilic nature of 1st generation antihistamines, the drugs belonging to 2nd generation antihistamines do not cross easily (if at all) through the bloodbrain barrier. Their propensity to occupy the H1 receptors in the CNS varies from 0% for fexofenadine to 30% for cetirizine (for 1st generation antihistamines it is 50-60%). Therefore these drugs are relatively free of sedating effects^{17,18}. The duration of action is 24 hours or more.

Astemizole and Terfenadine were withdrawn because of cardiac toxicity. The currently available 2nd generation antihistamines are free from cardiac toxicity even at higher than recommended doses. None of these drugs are available in parenteral form because of their low aqueous solubility.

The drugs belonging to 2nd generation antihistamines are Cetirizine, Levocetirizine, Loratadine, Desloratadine,

Fexofenadine, Rupatidine, Ebastine, Acrivastine and Mizolastine.

Sedation of Fexofenadine and Desloratadine have been compared to placebo. Loratadine has mild sedation compared to placebo¹⁹. Cetirizine²⁰ and Levocetirizine were found to have more sedation than the above three drugs.

Combination of Antihistamines: Treatment with two or more drugs of 2nd generation antihistamines is not recommended. Instead, up dosing of 2nd generation antihistamines is preferred²¹. Also, combined use of 1st generation and 2nd generation antihistamines is not recommended. However, if insomnia is a problem, 1st generation antihistamines may be administered at bed time along with a morning dose of 2nd generation antihistamines.

H2 receptor blockers : If the patient is not responding to high doses of H1 antihistamines, then H2 antihistamines like famotidine or ranitidine may be given simultaneously. The combination of H1 and H2 antihistamines have been found to be effective in a subgroup of patients with chronic urticaria²⁷.

Steroids and Cyclosporine: Oral/topical steroids are not recommended in the long term management of chronic urticaria. Cyclosporine 3 mg/kg/day has better safety profile than systemic steroids^{22,23}. But short course of oral steroids are indicated in acute or in episodic urticaria²⁴.

Drug treatment of Chronic Urticaria²¹

The step wise approach is -

1. 2nd generation antihistamines for 2 weeks
2. If not responding, 2nd generation antihistamines up dosing (2-4 times) for 1-4 weeks
3. If not responding, add Leukotriene antagonists and/or change 2nd generation antihistamines for 1-4 weeks
4. Other drugs: H2 receptor blockers, Cyclosporine, and Omalizumab may be tried in patients with chronic refractory urticaria.
5. Plasmapheresis in auto immune urticaria
6. Systemic steroids (3-7 days) in exacerbations.

Follow up - Re evaluate every 3-6 months as severity

may fluctuate and the need for 2nd generation antihistamines may stop. Spontaneous remission is seen usually within one year though in some cases it may prolong.

Treatment of Chronic Urticaria in special situations²⁶

Pregnancy: Cetirizine, Loratadine and Chlorpheniramine are in 'B' category whereas all other antihistamines are in 'C' category²⁵. Avoid 1st generation antihistamines during the third trimester because of risk of neonatal seizures¹⁴. Safety of up dosing of 2nd generation antihistamines is not known.

Children: Same line of management as in adults is to be followed. 1st generation antihistamines should be discouraged in children. Liquid formulations of Cetirizine and Loratadine are available.

Liver diseases: 1st generation antihistamines and some 2nd generation antihistamines undergo metabolism in liver. Safest Antihistamines are Cetirizine, Levocetirizine, Fexofenadine and Desloratadine.

Renal failure: Cetirizine and Levocetirizine are to be avoided in severe renal failure.

Summary

Chronic Urticaria is a "difficult to manage disease." The main reason is that most of the times, a definite cause can not be identified. The most important point is that investigations are of limited use in this disease, nor does it help in the treatment. Moreover it unnecessarily increases the anxiety of patients. The cornerstone of medical therapy is antihistamines. The newer second generation antihistamines are preferred over the older first generation antihistamines. Up dosing of the former is recommended over use of a combination of two 2nd generation antihistamines.

In a minority of patients, where aetiology is identified, its elimination is the most successful treatment measure.

References

1. Guidelines for evaluation and management of urticaria in adults and children Br J Dermatol 2007 Dec; 157(6):1116-23 Grattan C E, Humphreys F, British Association of Dermatologists Therapy Guidelines and Audit subcommittee.
2. Chronic urticaria. Aetiology, management and current

- and future treatment options. Kozel MMA, Sabroe RA: *Drugs*. 2004;64:2515-2536
3. Urticaria - Review article: Paulo Ricardo Criado, Roberta Fachini Jardim Criado, Celina W Maruta, Jose Eduardo Costa Martins et al *An Bras Dermatol* 2005; 80(6):613-32
 4. Sodium benzoate-induced repeated episodes of acute urticaria/angio-oedema: A randomized controlled trial. Nettis E, Colanardi MC, Ferrannini A, Tursi A *Br J Dermatol* 2004;151:898-902.
 5. The relationship between *Helicobacter pylori*, IgG antibody and autologous serum test in chronic urticaria. Hizal M, Tuzun B, Wolf R, Tuzun Y *Int J Dermatol*. 2000;39:443-5
 6. The effect of antibiotic therapy for patients infected with *Helicobacter pylori* who have chronic urticaria. Federman DJ, Kisner RS, Moriarty JP, Concato J *J Am Acad Dermatol* 2003;49:861-4
 7. Definition, classification, and routine diagnosis of urticaria: a consensus report. Zuberbier T, Greaves MW, Juhlin L, Kobza-Black A, Maurer D, Stingl G, et al *J Investig Dermatol Symp Proc*. 2001; 6:123-7
 8. Chronic urticaria and Angioedema Allen P Kaplan *New Engl J Med* Vol.346 No.3;175-179
 9. H1 Antihistamines in Allergic disease *Cas Motala Current Allergy and Clinical Immunology* June 2009, vol 22, No.2; 71-74
 10. Incidence and clinical importance of peroperative histamine release: randomised study of volume loading and antihistamines after induction of anaesthesia. Lorenz W, Duda D, Dick W, et al *Lancet* 1994; 343: 933-940.
 11. Advances in H1-Antihistamines. Simons FER. *N Eng J Med*. 2004;351:2203-2217
 12. Non H1-receptor effects of antihistamines. Church MK. *Clin Exp Allergy*. 1999; 29 (Suppl. 3):39-48
 13. H1-antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects. Leurs R, Church MK, Taglialatela M *Clin Exp Allergy*. 2002;32:489-498
 14. Chronic urticaria. Aetiology, management and current and future treatment options. Kozel MMA, Sabroe RA *Drugs*.2004;64:2515-2536
 15. EAACI/GA2LEN/EDF guideline: management of urticaria. Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CEH et al *Allergy*. 2006;6:321-331
 16. BSACI guidelines for the management of chronic urticaria and angio-oedema. Powell RJ, Du Toit GL, Siddique N, Leech SC et al *Clin Exp Allergy*. 2007;37:631-650
 17. Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and chlorpheniramine, a classical antihistamine. Tagawa M, Kano M, Okamura N et al *Br J Clin Pharmacol* 2001; 52: 501-509.
 18. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. Chishty M, Reichel A, Siva J, et al. *J Drug Target* 2001; 9: 223-228.
 19. Use of Antihistamines in Paediatrics A del Cuvillo, J Sastre, J Montoro, I Jáuregui et al *J Investig Allergol Clin Immunol* 2007; Vol. 17, Suppl. 2: 41-52
 20. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Raemaekers JG, Uiterwijk MMC, O'Hanlon JF. *Eur J Clin Pharmacol*. 1992; 42:363-369
 21. Position paper EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. Zuberbier T, Asero C, Bindslev-Jensen, G. Walter Canonica et al *Allergy* 2009; 64: 1427-1443
 22. Randomized double-blind study of cyclosporin in chronic idiopathic urticaria. Grattan CE, O'Donnell BF, Francis DM, Niimi N et al. *Br J Dermatol* 2000;143:365-372
 23. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. Vena GA, Cassano N, Colombo D, Peruzzi E et al. *J Am Acad Dermatol* 2006;55:705-709.
 24. Acute urticaria: clinical aspects and therapeutic responsiveness. Zuberbier T, Ifflander J, Semmler C, Henz BM. *Acta Derm Venereol* 1996;76:295-297
 25. Asthma and Immunological Diseases in Pregnancy and Early Infancy. Schatz M, Zeiger RS, Claman HN, ed. Marcel Dekker Inc, Nueva York. 1998; 141
 26. Antihistamines in the treatment of chronic urticaria. I Jáuregui, M Ferrer, J Montoro, I Dávila et al *J Investig Allergol Clin Immunol* 2007; Vol. 17, Suppl. 2: 41-52
 27. Lin RY, Curry A, Pesola GR, Knight RJ, Lee HS, Bakalchuk L, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. *Ann Emerg Med*. Nov 2000;36(5):462-8.